Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.

Del Rivero J, Edgerly M, Ward J, Madan RA, Balasubramaniam S, Fojo T, Gramza AW.

Oncologist. 2019 Jan;24(1):16-e14. doi: 10.1634/theoncologist.2018-0452. Epub 2018 Oct 8.


A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.

Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T.

Oncologist. 2017 Aug;22(8):888-e84. doi: 10.1634/theoncologist.2017-0211. Epub 2017 Jul 5.


Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.

Payabyab EC, Balasubramaniam S, Edgerly M, Velarde M, Merino MJ, Venkatesan AM, Leuva H, Litman T, Bates SE, Fojo T.

Clin Cancer Res. 2016 Oct 15;22(20):4989-5000.


Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T.

Oncologist. 2015 Jul;20(7):725-6. doi: 10.1634/theoncologist.2015-0104. Epub 2015 Jun 3.


Brain metastasis in patients with adrenocortical carcinoma: a clinical series.

Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly M, Fojo T.

J Clin Endocrinol Metab. 2015 Feb;100(2):331-6. doi: 10.1210/jc.2014-2650. Epub 2014 Nov 20.


The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T.

J Clin Endocrinol Metab. 2014 Apr;99(4):1291-7. doi: 10.1210/jc.2013-2298. Epub 2014 Jan 1.


Role of radiotherapy in adrenocortical carcinoma.

Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T, Kaushal A.

Cancer J. 2013 Jul-Aug;19(4):288-94. doi: 10.1097/PPO.0b013e31829e3221.


Combination chemotherapy in advanced adrenocortical carcinoma.

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group.

N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2.


A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T.

Clin Cancer Res. 2010 Mar 1;16(5):1634-41. doi: 10.1158/1078-0432.CCR-09-0379. Epub 2010 Feb 23.


Science, technology, and innovation: nursing responsibilities in clinical research.

Grady C, Edgerly M.

Nurs Clin North Am. 2009 Dec;44(4):471-81. doi: 10.1016/j.cnur.2009.07.011. Review.


Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.

Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE.

Cancer J. 2009 Sep-Oct;15(5):441-7. doi: 10.1097/PPO.0b013e3181be1b90. Review.


A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.

Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, Van Tellingen O, Bates SE, Fojo T.

Clin Cancer Res. 2009 May 15;15(10):3574-82. doi: 10.1158/1078-0432.CCR-08-0938. Epub 2009 May 5.


Is there room for improvement in adverse event reporting in the era of targeted therapies?

Edgerly M, Fojo T.

J Natl Cancer Inst. 2008 Feb 20;100(4):240-2. doi: 10.1093/jnci/djm324. Epub 2008 Feb 12.


A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T.

Cancer. 2005 May 1;103(9):1932-8.


Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.

Agrawal M, Edgerly M, Fojo T, Kotz H.

Gynecol Oncol. 2003 Jul;90(1):96-9.


Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T.

J Clin Oncol. 2003 May 1;21(9):1866-73.


Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC.

Clin Cancer Res. 2003 Feb;9(2):650-6.


Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection.

Sei S, Boler AM, Nguyen GT, Stewart SK, Yang QE, Edgerly M, Wood LV, Brouwers P, Venzon DJ.

AIDS. 2001 Jul 27;15(11):1343-52.


A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.

Mueller BU, Nelson RP Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, Wood LV, Zeichner S, Katz TT, Higham C, Aker D, Edgerly M, Jarosinski P, Serchuck L, Whitcup SM, Pizzuti D, Pizzo PA.

Pediatrics. 1998 Mar;101(3 Pt 1):335-43.


Supplemental Content

Loading ...
Support Center